TRAMP-C3; Prostate; Mouse (Mus musculus) Item ID: ATCCRL2732
| Permits and Restrictions |
View Permits View Restrictions |
|---|---|
| Organism | Mus musculus, transgenic, mouse, transgenic |
| Tissue | prostate |
| Cell Type | epithelial |
| Product Format | frozen |
| Morphology | epithelial |
| Culture Properties | adherent |
| Biosafety Level |
2 [Cells contain SV40 DNA viral sequences]
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Disease | adenocarcinoma |
| Age | adult |
| Gender | male |
| Strain | C57BL/6 (transgenic C57BL/6 mice heterozygous for the PB-T antigen transgene.) |
| Applications |
The cell lines can be used in studies to elucidate molecular mechanisms associated with the initiation, progression and metastasis of prostate cancer. They are also a useful tool for gene/drug discovery. |
| Storage Conditions | liquid nitrogen vapor phase |
| Derivation |
The TRAMP-C1 (ATCC CRL-2730), TRAMP- C2 (ATCC CRL-2731) and TRAMP-C3 (ATCC-CRL-2732) cell lines were derived in 1996 from a heterogeneous 32 week primary tumor in the prostate of a PB-Tag C57BL/6 (TRAMP) mouse. TRAMP is a transgenic line of C57BL/6 mice harboring a construct comprised of the minimal -426/+28 rat probasin promoter (426 base pairs of the rat probasin (PB) gene promoter and 28 base pairs of 5'-untranslated region) to target expression of the SV40 large T antigen to prostatic epithelium. |
|---|---|
| Receptor Expression | androgen receptor, expressed |
| Genes Expressed |
E-cadherin, cytokeratin |
| Cellular Products | E-cadherin cytokeratin |
| Tumorigenic | No |
| Effects | No, C57BL/6 hosts No, soft agar |
| Comments |
TRAMP-C1 and TRAMP-C2 are tumorigenic when grafted into syngeneic C57BL/6 hosts. Neither the cells grown in culture, nor the tumors arising from the cells in vivo, express SV40 T antigen (Tag). TRAMP-C1 and TRAMP-C2 are tumorigenic when grafted into syngeneic C57BL/6 hosts. However, TRAMP-C3 grows readily in vitro, but does not form tumors. These cell lines represent various stages of cellular transformation and progression to androgen-independent metastatic disease that can be manipulated in vitro. The cell lines can be used in studies to elucidate molecular mechanisms associated with the initiation, progression and metastasis of prostate cancer. They are also a useful tool for gene/drug discovery. |
| Complete Growth Medium | Dulbecco's modified Eagle's medium with 4 mM L-glutamine adjusted to contain 1.5 g/L sodium bicarbonate and 4.5 g/L glucose supplemented with 0.005 mg/ml bovine insulin and 10 nM dehydroisoandrosterone, 90%; fetal bovine serum, 5%; Nu-Serum IV, 5%. |
|---|---|
| Subculturing |
Volumes used in this protocol are for 75 cm2 flask; proportionally reduce or increase amount of dissociation medium for culture vessels of other sizes.
Subcultivation Ratio: 1:6 to 1:10Medium Renewal: Every 2 to 3 days Note: For more information on enzymatic dissociation and subculturing of cell lines consult Chapter 10 in Culture of Animal Cells, a Manual of Basic Technique by R. Ian Freshney, 3rd edition, published by Alan R. Liss, N.Y., 1994. |
| Cryopreservation | Complete growth medium supplemented with 5% (v/v) DMSO. Cell culture tested DMSO is available as ATCC Catalog No. 4-X. |
| Culture Conditions | Temperature: 37°C Atmosphere: Air, 95%; Carbon dioxide (CO2), 5% |
| Population Doubling Time | 37 hrs |
|---|
| Name of Depositor | N Greenberg |
|---|---|
| Year of Origin | 1996 |
| References |
Hurwitz AA, et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 94: 8099-8103, 1997. PubMed: 9223321 Foster BA, et al. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model. Cancer Res. 57: 3325-3330, 1997. PubMed: 9269988 Greenberg NM, et al. Prostate cancer in a transgenic mouse. Proc. Natl. Acad. Sci. USA 92: 3439-3443, 1995. PubMed: 7724580 Greenberg NM, et al. The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. Mol. Endocrinol. 8: 230-239, 1994. PubMed: 8170479 Gingrich JR, et al. Metastatic prostate cancer in a transgenic mouse. Cancer Res. 56: 4096-4102, 1996. PubMed: 8797572 Greenberg NM. Transgenic models for prostate cancer research. Urol. Oncol. 2: 119-122, 1996. Gingrich JR, et al. Androgen-independent prostate cancer progression in the TRAMP model. Cancer Res. 57: 4687-4691, 1997. PubMed: 9354422 Hay, R. J., Caputo, J. L., and Macy, M. L., Eds. (1992), ATCC Quality Control Methods for Cell Lines. 2nd edition, Published by ATCC. Caputo, J. L., Biosafety procedures in cell culture. J. Tissue Culture Methods 11:223-227, 1988. Fleming, D.O., Richardson, J. H., Tulis, J.J. and Vesley, D., (1995) Laboratory Safety: Principles and Practice. Second edition, ASM press, Washington, DC. Biosafety in Microbiological and Biomedical Laboratories, 5th ed. HHS. U.S. Department of Health and Human Services, Centers for Disease Control and Prevention. Washington DC: U.S. Government Printing Office; 2007. The entire text is available online. transgenic C57BL/6 mice heterozygous for the PB-T antigen transgene. |